DK1606317T3 - Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation - Google Patents

Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation

Info

Publication number
DK1606317T3
DK1606317T3 DK04749427.3T DK04749427T DK1606317T3 DK 1606317 T3 DK1606317 T3 DK 1606317T3 DK 04749427 T DK04749427 T DK 04749427T DK 1606317 T3 DK1606317 T3 DK 1606317T3
Authority
DK
Denmark
Prior art keywords
antibodies
binding partners
methods
well
inflammation
Prior art date
Application number
DK04749427.3T
Other languages
English (en)
Inventor
Pallavur V Sivakumar
Wenfeng Xu
Wayne Kindsvogel
Yasmin A Chandrasekher
Stacey R Dillon
Joyce M Lehner
Margaret D Moore
Anthony W Siadak
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1606317(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1606317T3 publication Critical patent/DK1606317T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04749427.3T 2003-03-24 2004-03-24 Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation DK1606317T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008956 WO2004085476A2 (en) 2003-03-24 2004-03-24 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
DK1606317T3 true DK1606317T3 (da) 2010-10-25

Family

ID=33101289

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04749427.3T DK1606317T3 (da) 2003-03-24 2004-03-24 Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation

Country Status (16)

Country Link
US (6) US20040209330A1 (da)
EP (2) EP1606317B1 (da)
JP (2) JP2007525438A (da)
KR (3) KR20110091598A (da)
CN (2) CN102690350A (da)
AT (1) ATE475673T1 (da)
AU (2) AU2004223837C1 (da)
BR (2) BRPI0408705A (da)
CA (2) CA2519089C (da)
DE (1) DE602004028347D1 (da)
DK (1) DK1606317T3 (da)
EA (2) EA009124B1 (da)
ES (1) ES2347657T3 (da)
MX (2) MXPA05010134A (da)
NO (1) NO20054892L (da)
WO (2) WO2004085475A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP2177616B1 (en) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
EP1351703B1 (en) 2000-09-15 2006-07-26 ZymoGenetics, Inc. Use of a polypeptide comprising the extracellular domains of il-20ra and il-20rb for the treatment of inflammation
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
ES2347657T3 (es) * 2003-03-24 2010-11-03 Zymogenetics, Inc. Anticuerpos dirigidos contra il-22ra y asociados de union y procedimiento de uso en inflamacion.
JP2007537993A (ja) * 2003-11-21 2007-12-27 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０受容体抗体および結合パートナーならびに炎症において用いる方法
CA2583202A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
DE602005022475D1 (de) * 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CA2596390A1 (en) * 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP1954719A2 (en) * 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
JP2009521503A (ja) * 2005-12-22 2009-06-04 ディー・エイチ・ワイ・アンド・カンパニー・リミテッド インターロイキン−２２結合タンパク質に対する抗体と、代謝性疾患の処置のためのその使用
WO2007109110A2 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
DK2202245T3 (da) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd Fremgangsmåde til modificering af et antistofs isoelektriske punkt via aminosyresubstitution i cdr
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
MY177564A (en) 2007-12-05 2020-09-20 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2670874T3 (es) 2011-03-16 2018-06-01 Argenx Bvba Anticuerpos contra CD70
DK2739748T3 (da) 2011-08-05 2019-06-24 Univ Aix Marseille Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
US8597647B1 (en) 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CN104583238A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
EP3284480A4 (en) 2015-04-14 2018-12-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
US20220177912A1 (en) * 2019-04-12 2022-06-09 The Methodist Hospital Therapeutic particles that enable antigen presenting cells to attack cancer cells
EP3984553A4 (en) * 2019-06-12 2023-07-19 Acurasysbio Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
JPH09509054A (ja) 1994-02-01 1997-09-16 アメリカ合衆国 抗体部分および非抗体部分を含む融合タンパク質
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999003982A1 (en) 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6020163A (en) * 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1719780A3 (en) * 1997-11-26 2006-12-20 ZymoGenetics, Inc. Mammalian cytokine-like polypeptide-10
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
NZ505880A (en) 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides
AU2871899A (en) 1998-03-09 1999-09-27 Schering Corporation Human receptor proteins; related reagents and methods
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
CA2347066C (en) 1998-10-26 2011-05-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
NZ515678A (en) 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
AU5151100A (en) 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE449109T1 (de) 1999-06-15 2009-12-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1230368A2 (en) 1999-11-18 2002-08-14 Schering Corporation Mammalian receptor proteins; related reagents and methods
CA2393369A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
CA2395539C (en) 1999-12-23 2009-08-25 Zymogenetics, Inc. Soluble interleukin-20 receptor
EP2295079A3 (en) * 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Method for treating inflammation
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
EP2177616B1 (en) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
EP1351703B1 (en) 2000-09-15 2006-07-26 ZymoGenetics, Inc. Use of a polypeptide comprising the extracellular domains of il-20ra and il-20rb for the treatment of inflammation
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
NZ527087A (en) 2001-01-12 2008-09-26 Genetics Inst Llc Type 2 cytokine receptor and nucleic acids encoding same
WO2002058724A2 (en) 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
NZ527396A (en) 2001-02-23 2007-12-21 Genetics Inst Llc Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
CA2433933A1 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
EP1370676A4 (en) 2001-03-02 2004-09-22 Zymogenetics Inc CYTOKIN RECEPTOR FROM MOUSE
WO2002072607A2 (en) * 2001-03-09 2002-09-19 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
EP1373508B1 (en) 2001-03-27 2013-04-24 ZymoGenetics, Inc. Human cytokine receptor
DK2163256T3 (da) * 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specifikke bindende proteiner og anvendelse deraf
US20040204351A1 (en) 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
UA93179C2 (ru) * 2003-03-24 2011-01-25 Займоджинетикс, Инк. Антитело, kotopoe специфически связывается c il-22ra, и способы его применения
ES2347657T3 (es) 2003-03-24 2010-11-03 Zymogenetics, Inc. Anticuerpos dirigidos contra il-22ra y asociados de union y procedimiento de uso en inflamacion.
JP2007537993A (ja) 2003-11-21 2007-12-27 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０受容体抗体および結合パートナーならびに炎症において用いる方法
DE602005022475D1 (de) * 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Also Published As

Publication number Publication date
ATE475673T1 (de) 2010-08-15
US20120207761A1 (en) 2012-08-16
US20100111948A1 (en) 2010-05-06
DE602004028347D1 (de) 2010-09-09
US20090074661A1 (en) 2009-03-19
MXPA05010136A (es) 2005-11-16
US20040209330A1 (en) 2004-10-21
CN102690350A (zh) 2012-09-26
WO2004085476A3 (en) 2005-03-31
KR20050116390A (ko) 2005-12-12
ES2347657T3 (es) 2010-11-03
KR20110091598A (ko) 2011-08-11
AU2004223837A1 (en) 2004-10-07
WO2004085476A2 (en) 2004-10-07
EP1606317B1 (en) 2010-07-28
EP1606317A2 (en) 2005-12-21
JP2007525437A (ja) 2007-09-06
WO2004085475A2 (en) 2004-10-07
EA009124B1 (ru) 2007-10-26
AU2004223836A2 (en) 2004-10-07
AU2004223837C1 (en) 2012-03-15
KR20050116392A (ko) 2005-12-12
EA200501506A1 (ru) 2006-06-30
CN103864934A (zh) 2014-06-18
US8163286B2 (en) 2012-04-24
CA2519089C (en) 2014-12-23
EA009026B1 (ru) 2007-10-26
AU2004223837A2 (en) 2004-10-07
EA200501505A1 (ru) 2006-06-30
MXPA05010134A (es) 2005-11-16
CA2519057A1 (en) 2004-10-07
US20060134756A1 (en) 2006-06-22
AU2004223837B2 (en) 2011-04-21
JP2007525438A (ja) 2007-09-06
AU2004223836A1 (en) 2004-10-07
EP1606316A2 (en) 2005-12-21
NO20054892D0 (no) 2005-10-21
BRPI0408705A (pt) 2006-03-07
NO20054892L (no) 2005-12-23
CA2519089A1 (en) 2004-10-07
US20080233115A1 (en) 2008-09-25
WO2004085475A3 (en) 2005-07-14
BRPI0408683A (pt) 2006-03-28

Similar Documents

Publication Publication Date Title
DK1606317T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
DK1812476T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
DK1931697T3 (da) IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
WO2004045525A3 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ATE408624T1 (de) Verfahren zur reinigung von fsh
IL192950A0 (en) Soluble il-17rcx4 and methods of using in inflammation
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
DE60040089D1 (de) Menschliches homolog aus der familie der metalloproteasen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение